methyl N-[(1R)-2-[(2S,3aR,7aR)-2-[5-[4-[2-[(2S,3aR,7aR)-1-[(2R)-2-(methoxycarbonylamino)-2-phenylacetyl]-2,3,3a,4,5,6,7,7a-octahydroindol-2-yl]-3H-benzimidazol-5-yl]phenyl]-1H-imidazol-2-yl]-2,3,3a,4,5,6,7,7a-octahydroindol-1-yl]-2-oxo-1-phenylethyl]carbamate

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: methyl N-[(1R)-2-[(2S,3aR,7aR)-2-[5-[4-[2-[(2S,3aR,7aR)-1-[(2R)-2-(methoxycarbonylamino)-2-phenylacetyl]-2,3,3a,4,5,6,7,7a-octahydroindol-2-yl]-3H-benzimidazol-5-yl]phenyl]-1H-imidazol-2-yl]-2,3,3a,4,5,6,7,7a-octahydroindol-1-yl]-2-oxo-1-phenylethyl]carbamate
• 化学式: C₅₂H₅₆N₈O₆
• 分子量: 889.0
• InChiKey: XKRDCRNLSVPWEU-RMNRUEBASA-N

计算性质

• 辛醇/水分配系数(LogP)：
  8.2
• 重原子数：
  66
• 可旋转键数：
  12
• 环数：
  10.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  175
• 氢给体数：
  4
• 氢受体数：
  8

文献信息

• NOVEL BENZIMIDAZOLE DERIVATIVES
  申请人：ENANTA PHARMACEUTICALS, INC.

  公开号：US20140193363A1

  公开（公告）日：2014-07-10

  The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: which inhibit RNA-containing virus, particularly the hepatitis C virus (HCV). Consequently, the compounds of the present invention interfere with the life cycle of the hepatitis C virus and are also useful as antiviral agents. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from HCV infection. The invention also relates to methods of treating an HCV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.
• US20140341851A1
  申请人：——

  公开号：US20140341851A1

  公开（公告）日：2014-11-20
• US9765087B2
  申请人：——

  公开号：US9765087B2

  公开（公告）日：2017-09-19